Skip Navigation


Annals of Oncology Advance Access originally published online on February 23, 2009
Annals of Oncology 2009 20(6):1080-1085; doi:10.1093/annonc/mdn751
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
20/6/1080    most recent
mdn751v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in Ann Oncol
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Falchook, G. S.
Right arrow Articles by Pro, B.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Falchook, G. S.
Right arrow Articles by Pro, B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

hematologic malignancies

Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment

G. S. Falchook1, F. Vega2, N. H. Dang1, F. Samaniego1, M. A. Rodriguez1, R. E. Champlin3, C. Hosing3, S. Verstovsek4 and B. Pro1,*

1 Department of Lymphoma/Myeloma
2 Department of Hematopathology
3 Department of Stem Cell Transplantation and Cellular Therapy
4 Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, USA

* Correspondence to: Dr B. Pro, Department of Lymphoma/Myeloma, Unit 429, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA. Tel: +1+713-792-2860; Fax: +1-713-794-5656; E-mail: bpro{at}mdanderson.org

Background: Hepatosplenic T-cell lymphoma (HSTCL) is a rare peripheral T-cell lymphoma; treatment with standard anthracycline-containing chemotherapy regimens has been disappointing, and an optimal treatment strategy for this patient population has not yet been determined.

Methods: We identified 15 cases of pathologically confirmed HSTCL in the institution's database. Clinical characteristics and treatment results were reviewed.

Results: Complete responses (CRs) were achieved in 7 of 14 patients who received chemotherapy. Achievement of CR was followed by hematopoietic stem-cell transplantation in three patients. Median duration of CR was 8 months (range 2 to 32+ months) with four patients currently alive and in CR at 5, 8, 12, and 32 months, respectively. Median overall survival (OS) was 11 months (range 2 to 36+ months). Patients who achieved a CR had a median OS of 13 months, compared with 7.5 months in patients who did not achieve a CR. Risk factors associated with worse outcome included male gender, failure to achieve a CR, history of immunocompromise, and absence of a T-cell receptor gene rearrangement in the gamma chain.

Conclusion: A better understanding of the pathophysiology of HSTCL and new therapeutic strategies are needed.

Key words: clinicopathological features, hematopoietic stem-cell transplantation, hepatosplenic T-cell lymphoma, treatment

Received for publication November 11, 2008. Accepted for publication November 19, 2008.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in Ann Oncol:

in this issue

Ann Oncol 2009 20: 971. [Extract] [Full Text]  





Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.